Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.

@article{Hu2009LongtermEA,
  title={Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.},
  author={Jiong Yu Hu and Yuan-fang Liu and Chuan-Feng Wu and Fang Xu and Zhi-xiang Shen and Yong-mei Zhu and Jun-min Li and Wei Zhen Tang and Wei-Li Zhao and Wen Wu and Hui-ping Sun and Qiu-sheng Chen and Bing Chen and Guang-Biao Zhou and Arthur Zelent and Samuel Waxman and Zhen-yi Wang and Sai-juan Chen and Zhu Chen},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2009},
  volume={106 9},
  pages={3342-7}
}
All-trans retinoic acid (ATRA)/arsenic trioxide (ATO) combination-based therapy has benefitted newly diagnosed acute promyelocytic leukemia (APL) in short-term studies, but the long-term efficacy and safety remained unclear. From April 2001, we have followed 85 patients administrated ATRA/ATO with a median follow-up of 70 months. Eighty patients (94.1%) entered complete remission (CR). Kaplan-Meier estimates of the 5-year event-free survival (EFS) and overall survival (OS) for all patients were… CONTINUE READING
118 Citations
47 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 118 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia

  • GC Zhang
  • Chin J Cancer 23:430–434
  • 2008

Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia

  • A Aribi
  • Cancer
  • 2007

Similar Papers

Loading similar papers…